Get the Stockscreener App
5.40
9.85%
-0.59
Creative Medical Technology Holdings Inc stock is traded at $5.40, with a volume of 99,855.
It is down -9.85% in the last 24 hours and up +133.26% over the past month.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
See More
Previous Close:
$5.99
Open:
$5.82
24h Volume:
99,855
Relative Volume:
1.65
Market Cap:
$9.44M
Revenue:
$102.80K
Net Income/Loss:
$-5.32M
P/E Ratio:
-1.4211
EPS:
-3.8
Net Cash Flow:
$-5.45M
1W Performance:
+13.92%
1M Performance:
+133.26%
6M Performance:
+69.65%
1Y Performance:
+25.58%
1-Day Range:
$5.26
$5.97
1-Week Range:
$4.50
$6.90
52-Week Range:
$1.957
$10.28
Creative Medical Technology Holdings Inc Stock (CELZ) Company Profile
Name
Creative Medical Technology Holdings Inc
Sector
Industry
Phone
480-399-2822
Address
211 E. OSBORN RD., PHOENIX
Compare CELZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELZ
Creative Medical Technology Holdings Inc
|
5.40 | 9.44M | 102.80K | -5.32M | -5.45M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Creative Medical Technology Holdings Inc Stock (CELZ) Latest News
Allworth Financial LP Raises Stake in Align Technology, Inc. (NASDAQ:ALGN) - Defense World
Creative medical technology director Michael Finger sells $8,062 in stock - Investing.com
Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential - The Manila Times
Aterian Issues Letter to Shareholders - The Manila Times
This Groundbreaking Fertility Treatment Could Make IVF ObsoleteNew Presidential Order Accelerates Access - StockTitan
Roth Capital Has Negative Outlook for CELZ FY2028 Earnings - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Creative Medical Technology Reports Mid-Term Data Showing Reduced Opioid Use With StemSpine - Nasdaq
Creative Medical Technology rises on positive data for stem cell therapy - TradingView
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™ - The Manila Times
Fortis Inc. Files 2024 Year-End Disclosure Documents - The Manila Times
Revolutionary Back Pain Therapy Frees 90% of Patients from Opioid Dependency in Landmark Study - StockTitan
Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose - Patient Care Online
Mergers & Acquisitions Tracker - Plastics News
Creative Medical reports progress in Type 2 Diabetes treatment - MSN
Critical Analysis: Creative Medical Technology (NASDAQ:CELZ) vs. Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
EGenesis Deems Second Transplant of Genetically Modified Porcine Kidney EGEN-2784 Successful - CGTLive™
Investigational Cell Therapy Cuts Insulin Dependency in Late-Stage Type 2 Diabetes - Patient Care Online
Creative Medical Technology’s Cell Therapy AlloStem Reduces Insulin Dependency in Late-Stage Type 2 Diabetes - CGTLive™
Creative Medical reports progress in Type 2 Diabetes treatment By Investing.com - Investing.com Australia
CELZ-201 Cuts Insulin Dependency at 1 Year in Patients with Type 2 Diabetes - MD Magazine
Creative Medical Technology's CELZ-201 Shows 80% Efficacy In Type 2 Diabetes Trial - Nasdaq
Aspirin, NSAID Use Linked to Lower Cancer, Mortality Risk in Chronic Liver Diseases - MD Magazine
Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program - The Manila Times
Revolutionary Diabetes Breakthrough: CELZ's AlloStem™ Slashes Insulin Dependency in Clinical Trial - StockTitan
In Food Allergy, Exposure to Store-Bought Peanut Butter Bests Avoidance Strategies - MD Magazine
BLA Submission Planned for CORDStrom in RDEB - MD Magazine
Clinical Quiz: Diagnosis and Biomarkers in Anaphylaxis - MD Magazine
Long-Term VIVID-2 Data for Mirikizumab in Crohn’s Disease, with Edward Barnes, MD, MPH - MD Magazine
Nerandomilast Meets Primary Endpoint in Improving FVC in Progressive Pulmonary Fibrosis - MD Magazine
Trading Update: Ford Motor Co (F) Stock Endures 2.56% Monthly Volatility - The News Heater
PDD Holdings Inc ADR (PDD) Shares Rise Despite Market Challenges - The News Heater
Creative Medical enhances diabetes treatment with AI tech - MSN
Creative Medical Technology Holdings (CELZ): AI-Enhanced Stem Cell Therapy for Diabetes - Insider Monkey
12 AI News and Ratings Investors are Keeping Their Eye On - Insider Monkey
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz - EIN News
Creative Medical enhances diabetes treatment with AI tech By Investing.com - Investing.com South Africa
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development - The Manila Times
Breakthrough: AI Accelerates Diabetes Cure Research as Creative Medical Doubles Development Speed - StockTitan
EvokAI Creative Labs Sets Date for Share Consolidation - Yahoo Finance
Clinical Trials News Live Feed - StockTitan
Nisa Investment Advisors LLC Acquires 4,234 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) - Defense World
Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain - The Manila Times
Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from - EIN News
Revolutionary Stem Cell Therapy Tackles Chronic Back Pain: First Trial Results Unveiled - StockTitan
La Rosa Holdings Corp. Appoints Commercial Real Estate Veteran JM Padron to Lead National Expansion of - EIN News
Odyssey Trust Company Appoints Bryce Szela as Chief Growth Officer - EIN News
Shoals Technologies Group, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and - EIN News
Equinix, Inc. (Nasdaq: EQIX) Investor Alert: Grabar Law Investigates Claims as Securities Fraud Class Action - EIN News
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update - EIN News
Silvercrest Asset Management Group Inc. Announces Quarterly Dividend - EIN News
Creative Medical Technology Holdings Inc Stock (CELZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Creative Medical Technology Holdings Inc Stock (CELZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Finger Michael H. | Director |
Feb 18 '25 |
Sale |
5.00 |
750 |
3,750 |
1,101 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):